{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T08:50:45Z","timestamp":1676105445288},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s11899-009-0028-z","type":"journal-article","created":{"date-parts":[[2009,9,30]],"date-time":"2009-09-30T07:16:19Z","timestamp":1254294979000},"page":"213-217","source":"Crossref","is-referenced-by-count":3,"title":["Frontline therapy in mantle cell lymphoma: The role of high-dose therapy and integration of new agents"],"prefix":"10.1007","volume":"4","author":[{"given":"Brad S.","family":"Kahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,1]]},"reference":[{"key":"28_CR1","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood 1997, 89:3909\u20133918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"28_CR2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A. Herrmann","year":"2009","unstructured":"Herrmann A, Hoster E, Zwingers T, et al.: Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009, 27:511\u2013518.","journal-title":"J Clin Oncol"},{"key":"28_CR3","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1200\/JCO.2006.08.7999","volume":"25","author":"D. Kienle","year":"2007","unstructured":"Kienle D, Katzenberger T, Ott G, et al.: Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors. J Clin Oncol 2007, 25:2770\u20132777.","journal-title":"J Clin Oncol"},{"key":"28_CR4","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","volume":"7","author":"P. Jares","year":"2007","unstructured":"Jares P, Colomer D, Campo E: Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7:750\u2013762.","journal-title":"Nat Rev Cancer"},{"key":"28_CR5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.2008.19.5032","volume":"27","author":"P. Martin","year":"2009","unstructured":"Martin P, Coleman M, Leonard JP: Progress in mantle-cell lymphoma. J Clin Oncol 2009, 27:481\u2013483.","journal-title":"J Clin Oncol"},{"key":"28_CR6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","volume":"3","author":"A. Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A, et al.: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185\u2013197.","journal-title":"Cancer Cell"},{"key":"28_CR7","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2007.12.0410","volume":"26","author":"E. Hartmann","year":"2008","unstructured":"Hartmann E, Fernandez V, Moreno V, et al.: Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol 2008, 26:4966\u20134972.","journal-title":"J Clin Oncol"},{"key":"28_CR8","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","volume":"111","author":"O. Determann","year":"2008","unstructured":"Determann O, Hoster E, Ott G, et al.: Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008, 111:2385\u20132387.","journal-title":"Blood"},{"key":"28_CR9","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","volume":"107","author":"T. Katzenberger","year":"2006","unstructured":"Katzenberger T, Petzoldt C, H\u00f6ller S, et al.: The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006, 107:3407.","journal-title":"Blood"},{"key":"28_CR10","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E. Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, et al.: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111:558\u2013565.","journal-title":"Blood"},{"key":"28_CR11","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G. Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, et al.: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984\u20131992.","journal-title":"J Clin Oncol"},{"key":"28_CR12","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","volume":"20","author":"O.M. Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS, et al.: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002, 20:1288\u20131294.","journal-title":"J Clin Oncol"},{"key":"28_CR13","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"J.E. Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, et al.: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013\u20137023.","journal-title":"J Clin Oncol"},{"issue":"Suppl2","key":"28_CR14","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.3816\/CLM.2007.s.034","volume":"8","author":"L. Fayad","year":"2007","unstructured":"Fayad L, Thomas DA, Romaguera J: Update of the M.D. Anderson Cancer Center experience with hyperCVAD and rituximab for the treatment of mantle cell and Burkitttype lymphomas. Clin Lymphoma Myeloma 2007, 8(Suppl 2):S57\u2013S62.","journal-title":"Clin Lymphoma Myeloma"},{"key":"28_CR15","doi-asserted-by":"crossref","unstructured":"Epner E, Unger JM, Miller TP, et al.: A multi center trial of hyperCVAD + Rituxan in patients with newly diagnosed mantle cell lymphoma [abstract 387]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 387.","DOI":"10.1182\/blood.V110.11.387.387"},{"key":"28_CR16","first-page":"285","volume":"112","author":"M. Dreyling","year":"2008","unstructured":"Dreyling M, Hoster E, van Hoof A, et al.: Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission of mantle cell lymphoma [abstract 769]. Blood (ASH Annual Meeting Abstracts) 2008, 112:285.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"28_CR17","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M. Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, et al.: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105:2677\u20132684.","journal-title":"Blood"},{"key":"28_CR18","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"C.H. Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, et al.: Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687\u20132693.","journal-title":"Blood"},{"key":"28_CR19","first-page":"218","volume":"112","author":"R. Delarue","year":"2008","unstructured":"Delarue R, Haioun C, Ribrag V, et al.: RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma: final results of a phase II study from the GELA [abstract 581]. Blood (ASH Annual Meeting Abstracts) 2008, 112:218.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"28_CR20","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"R.I. Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, et al.: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867\u20134874.","journal-title":"J Clin Oncol"},{"key":"28_CR21","first-page":"104","volume":"112","author":"B. Kahl","year":"2008","unstructured":"Kahl B, Chang J, Eickhoff J, et al.: VcR-CVAD produces a high complete response rate in untreated mantle cell lymphoma: a phase II study from the Wisconsin Oncology Network [abstract 265]. Blood (ASH Annual Meeting Abstracts) 2008, 112:104.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"28_CR22","doi-asserted-by":"crossref","unstructured":"Smith M, Zhang L, Gordon L, et al.: Phase II study of RCHOP followed by 90 Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499 [abstract 389]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 389.","DOI":"10.1182\/blood.V110.11.389.389"},{"key":"28_CR23","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","volume":"17","author":"B. Kahl","year":"2006","unstructured":"Kahl B, Longo W, Eickhoff J, et al.: Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006, 17:1418\u20131423.","journal-title":"Ann Oncol"},{"key":"28_CR24","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G. Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, et al.: Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27:3822\u20133829.","journal-title":"J Clin Oncol"},{"key":"28_CR25","doi-asserted-by":"crossref","unstructured":"Reeder C, Gornet M, Habermann T, et al.: A phase II trial of the oral mTOR inhibitor everolimus (RADOO1) in relapsed aggressive non-Hodgkin lymphoma [abstract 121]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 121.","DOI":"10.1182\/blood.V110.11.121.121"},{"key":"28_CR26","first-page":"104","volume":"112","author":"P.L. Zinzani","year":"2008","unstructured":"Zinzani PL, Witzig TE, Vose JM, et al.: Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle cell lymphoma: results of an international study (NHL-003) [abstract 262]. Blood (ASH Annual Meeting Abstracts) 2008, 112:104.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"28_CR27","first-page":"900","volume":"112","author":"M. Rummel","year":"2008","unstructured":"Rummel M, von Gruenhagen U, Niederle N, et al.: Bendamustine plus rituximab versus CHOP plus rituximab in the first line treatment of patients with follicular, indolent, and mantle cell lymphomas: results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL) [abstract 2596]. Blood (ASH Annual Meeting Abstracts) 2008, 112:900.","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0028-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-009-0028-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0028-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T16:24:42Z","timestamp":1590164682000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-009-0028-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["28"],"URL":"https:\/\/doi.org\/10.1007\/s11899-009-0028-z","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}